TransMedics Group - TMDX Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 12 month price targets for TransMedics Group's shares. Their TMDX share price forecasts range from $45.00 to $85.00. On average, they expect the company's stock price to reach $71.57 in the next twelve months. This suggests that the stock has a possible downside of 5.5%.
View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts.

TransMedics Group's stock was trading at $61.72 on January 1st, 2023. Since then, TMDX stock has increased by 22.7% and is now trading at $75.73.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our TMDX earnings forecast.

TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings results on Wednesday, February, 22nd. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. The company earned $31.38 million during the quarter, compared to analysts' expectations of $23.60 million. TransMedics Group had a negative net margin of 38.77% and a negative trailing twelve-month return on equity of 29.82%. TransMedics Group's quarterly revenue was up 224.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.46) earnings per share.

ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), Alger 35 ETF (ATFV), SPDR S&P Health Care Equipment ETF (XHE), Invesco DWA SmallCap Momentum ETF (DWAS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Fidelity Growth Opportunities ETF (FGRO).

TransMedics Group updated its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$145.00 million, compared to the consensus revenue estimate of $134.71 million.

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

(TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMDX stock can currently be purchased for approximately $75.73.

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.44 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

The company employs 148 workers across the globe.

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.